Advertisement Pharmaceutical Business review - Page 708 of 5291 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 22, 2026

EC approves Menarini and NewAmsterdam’s obicetrapib therapies

The European Commission (EC) has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo (obicetrapib 10mg monotherapy) and Evlarco (10mg obicetrapib plus 10mg ezetimibe fixed-dose combination).

Obicetrapib is being developed as a low-dose, oral CETP inhibitor for lowering LDL cholesterol in patients unresponsive to treatments. Credit: PeopleImages / Shutterstock.com.